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Background/aim: Allergic rhinitis (AR) is a respiratory disease caused by inflammation of the nasal mucosa. Intranasal corticosteroids
(ICs) are an effective treatment for AR; however, their use has been associated with atrophy in nasal mucosae. Because DNA damage
has been linked to several chronic diseases, we hypothesize that use of ICs could cause DNA damage in nasal mucosa cells, leading to
mucosal atrophy and septal perforation.
Materials and methods: Sixty patients with moderate or severe AR were divided randomly into two groups. Mometasone furoate (MF)
and antihistamine tablets (desloratadine) were given to the study (IC) group. Physiologic saline and desloratadine were given to the
control ((serum physiologic (SP)) group. Nasal irrigation fluid was taken from patients before study commencement and after 4 weeks
of treatment. The comet assay was applied to detect DNA damage in nasal mucosa cells.
Results: Nineteen patients were excluded, leaving a study population of 41 patients (IC group: 17 patients; SP group: 24 patients).
Genotoxic damage was evaluated by comet assay.
Conclusion: Treatment with MF spray for 4 weeks does not cause DNA breaks within cells in the nasal mucosa. These results could form
the basis of clinical trials involving treatment with different ICs over longer treatment periods.
Key words: Allergic rhinitis, allergic rhinitis and its impact on asthma, mometasone furoate, comet assay, intranasal corticosteroids

1. Introduction
Allergic rhinitis (AR) is a major chronic respiratory
disease (1). Its prevalence, impact on quality of life, and
association with comorbidities, such as asthma, are
important (1). AR is caused by inflammation in the nasal
mucosa, and appears as a type-1 hypersensitivity reaction.
Approximately 50%–80% of all cases of rhinitis are due to
AR (2). AR appears to be more prevalent in urban than in
rural areas (2,3). Worldwide prevalence of AR is 25%–35%
(4), whereas it is 15% in Turkey, and tends to be higher in
children and young adults (5).
AR is characterized by sneezing, rhinorrhea, nasal
itching, and nasal congestion (6). These symptoms
occur because of mediator (histamine, prostaglandins,
leukotrienes, cytokines, chemotactic factors) release
from inflammatory cells that migrate to the nasal mucosa
(6). The effects of topical corticosteroids are inhibition
of aggregation of inflammatory cells in the airway,
suppression of local production of cytokines, prevention
of mediator release, and repair of the structure of the nasal
mucosa (7).
* Correspondence: hakanak1985@hotmail.com

Corticosteroids administered within the nasal cavity
((intranasal corticosteroids (ICs)) have been used as an
effective and safe treatment for various diseases of nasal
sinuses (e.g., AR, vasomotor rhinitis) since the 1970s (8).
AR incidence is increasing in tandem with the use of ICs.
Many patients use ICs for months or years (9). Side effects
are often reported for ICs, and include burning sensations,
dryness, bleeding, and septal perforation within the nose
(8,10–12). Atrophic changes in the nasal mucosa have been
noted, especially in the first 4 weeks of IC treatment (13).
However, the mechanism of action of this side effect is not
known.
Deoxyribonucleic acid (DNA) is very sensitive to
damage and is the target of various reactive molecules.
DNA damage, also known as genotoxic damage, can be
spontaneous during DNA metabolism or can be attributed
to the effects of environmental factors. It has been implicated
in numerous diseases, such as cancer and inflammatory
diseases, and is evaluated when monitoring chronic
degenerative diseases, effectiveness of chemotherapy and
radiotherapy, and genotoxic effects of medications.
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The comet assay, also known as alkaline single cell gel
electrophoresis (SCGE), is a noninvasive, rapid, precise
fluorescent microscopic method. It can be applied to
detect DNA damage and different cell types as well as
determining the extent and type of damage.
Our hypothesis is that side effects in the nose, such as
mucosal atrophy and septal perforation, are dependent on
DNA damage, which can lead to apoptosis. The purpose
of our study was to investigate the use of mometasone
furoate (6) (MF; an active ingredient of an IC, commonly
used in Turkey), its efficacy, and the pathophysiology of its
side effects.
2. Materials and methods
The present study was conducted in collaboration with
the Departments of Otolaryngology, Pediatric Allergy,
and Medical Biology of the Faculty of Medicine, Başkent
University, Ankara, Turkey. This study was approved by
the Institutional Review Board and Ethics Committee
of Başkent University (Project No. KA14/203). It was
a prospective, controlled, double-blind clinical study.
All participants were informed about the methods and
potential risks of the study. Written informed consent was
provided by all subjects.
2.1. Patients
The study was carried out between September 2014 and
April 2015. The inclusion criteria were as follows: diagnosis
of moderate or severe AR, according to allergic rhinitis
and its impact on asthma (ARIA) criteria (14); positive
(>3 mm) skin-prick test or epicentral leather-prick test,
undertaken by the Pediatric Allergy Department and
indicating medical treatment; males or females aged 18–
65 years; history of AR symptoms (sneezing, rhinorrhea,
nasal itching, nasal congestion); no use of systemic or
topical corticosteroids in the previous month; and no viral
or bacterial infections of the upper airways in the previous
month.
We excluded patients who consumed alcohol or smoked
tobacco; were undergoing immunotherapy or systemic
immunosuppressive therapy; were using antihistamines,
leukotriene antagonists, anti-lgE monoclonal antibodies,
or decongestant drugs; were suffering from diabetes
mellitus, asthma, cancer, cystic fibrosis, or other chronic
inflammatory diseases; had advanced deviation of the nasal
septum, nasal polyps, nasopharyngeal disease, or who had
undergone nasal surgery previously; had infection of the
upper respiratory tract during the first month of treatment;
were suffering from epistaxis; or were pregnant.
Sixty patients met the inclusion criteria. The patients
had not used any treatment for allergic rhinitis before.
They were randomly divided into two groups using
the sealed envelope method. IC and antihistamine
tablets (desloratadine) were given to the study (IC)
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group. Physiologic (0.9%) saline and antihistamine
tablets (desloratadine) were given to the control (serum
physiologic (SP)) group. Identical antihistamine tablets
were given to both groups, so that patients diagnosed with
AR were not left untreated and the homogeneity of the two
groups was ensured. Mechanical trauma was supplied by
administration of IC spray to the IC group and physiologic
serum spray to the SP group. Patients used the IC spray
or physiologic serum spray every day for 4 weeks at an
identical frequency and in equal doses. Each group used a
single dose of the same antihistamine on 1 day during the
4 weeks. In the IC group, patients administered two puffs
of IC spray (MF) into each nasal passage in the morning
and evening. Each spray provided 100 µg of MF to the
nasal passage. In the SP group, patients administered two
puffs of 0.9% sodium chloride into each nasal passage in
the morning and evening.
Cells from the nasal mucosae of patients were obtained
before study commencement and at the end of 4 weeks of
treatment. Patients were asked not to wipe their noses on
the morning that samples were to be taken. Patients were
seated, 3.5 mL of saline was injected (using a 5-mL injector)
into the right nasal passage, and a sterile container was used
to collect the nasal wash. Then the curettage procedure was
performed 2–3 times to the right nasal passage to release
cells, and 3.5 mL of saline was injected into the right nasal
passage by providing flow-exposed cells in the container.
The same process was applied to the left nasal passage, and
all nasal wash fluid was collected in the same container.
The resultant nasal wash fluid was taken to the Medical
Biology Laboratory on the same day. Absence or presence
of genotoxic damage to cells (15,16), obtained from nasal
wash fluid from both groups, was determined using CA
(17–21) by a researcher who was not involved in sample
procurement.
2.2. Alkaline comet assay (alkaline single cell gel
electrophoresis)
For the determination of genotoxic damages of patients,
alkaline SCGE was performed as previously described
(22). In brief, nasal wash fluids were centrifuged at 500 ×
g for 10 min. Supernatants were removed and cell pellets
were resuspended in phosphate-buffered saline (PBS). Cell
suspension, mixed with low melting point agarose (LMPA;
Sigma–Aldrich, USA), was added onto the slides, which
had been precoated with normal melting point agarose
(NMPA; Sigma–Aldrich, USA). Coverslips were placed
and were removed after the solidification of the agarose.
Finally, a third layer of NMPA was added over the slides.
After solidification of the third layer of NMPA, slides were
incubated in a lysis solution at 4 °C (dark) for 2 h. Slides
were incubated in an alkaline electrophoresis buffer for
20 min in the dark, and electrophoresis was performed at
24 V (300 mA) for 30 min. Slides were neutralized in a
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neutralization buffer and stained with 2 µg/mL ethidium
bromide. Cells were scored under fluorescence microscope
(Nikon, Eclipse 600, Japan). A minimum of two SCGE
slides were prepared from each sample and 300 nuclei were
evaluated by visual scoring. Nuclei were scored as 0, 1+, 2+,
3+, and 4+ by a blinded observer, according to the apparent
relative proportion of DNA in the tail and head, as shown
in Figures 1–5. Each counted nucleus was multiplied by its
score, and total scores were expressed as AU.
2.3. Statistical analyses
Data analyses were undertaken using SPSS 11.5 (SPSS
Inc., Chicago, IL, USA). Continuous and discontinuous
numerical variables were investigated for normal and
nonnormal distribution, using the Kolmogorov–Smirnov
test. Significance of differences among groups for mean and
median values was ascertained with the Mann–Whitney
U-test. Categorical variables were analyzed with Pearson’s
chi-square test or Fisher’s exact test. Correlation between
continuous and discontinuous variables was ascertained
using Spearman’s correlation test. A value of P < 0.05 was
considered significant.
3. Results
Among the 60 patients at study commencement, 9 patients
did not attend for treatment, epistaxis was observed in
one patient, and respiratory tract infection was observed
in 9 patients. Hence, 19 patients were excluded from the
study, leaving a study population of 41 patients. Seventeen
patients (41.46%) were in the IC group ((8 female (19.51%)
and 9 male (21.95%)). Twenty-four patients (58.54) were in
the SP group ((14 female (34.15%) and 10 male (24.39%)).
The sex distribution of patients is shown in Table 1. There
was no significant difference between groups in terms of
sex (P > 0.05). The age range of 41 patients was 20–58 years
(median, 27; mean, 30.70 ± 9.31). The age range of the IC
group was 20–51 years (median, 27; mean, 30.18 ± 9.07),
whereas that of the SP group was 20–58 years (28; 31.08 ±
9.65). The age distribution of the patients is shown in Table
2. There was no significant difference between the groups
in terms of age (P > 0.05).
Mean comet score for 41 patients was 44.03 ± 21.72
before treatment and 49.38 ± 19.25 after treatment. Mean
comet score was 43.96 ± 25.34 before treatment and 48.07
± 23.99 after treatment in the IC group. Mean comet score
was 44.08 ± 19.33 before treatment and 50.30 ± 15.55 after
treatment in the SP group. No significant difference was
observed before and after treatment for mean comet scores
within or between groups (P = 0.272). The comet scores of
the patients are shown in Table 3.
4. Discussion
ICs have been used for the treatment of AR since the
1970s. The clinical effects of topical corticosteroids are

Figure 1. Appearance of a cell with comet scoring 0.

Figure 2. Appearance of a cell with comet scoring 1+.

Figure 3. Appearance of a cell with comet scoring 2+.
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Figure 5. Appearance of a cell with comet scoring 4+.

Figure 4. Appearance of a cell with comet scoring 3+.
Table 1. Sex distribution of patients.
Male

SP

Female

Total

Number

%

Number

%

Number

%

10

24.39

14

34.15

24

58.54

MF

9

21.95

8

19.51

17

41.46

Total

19

46.34

22

53.66

41

100

Table 2. Age distribution of patients.

SP

Mean

Number

Std. [±]

Median

Minimum

Maximum

31.08

24

9.65

28.00

20.00

58.00

MF

30.18

17

9.07

27.00

20.00

51.00

Total

30.70

41

9.31

27.00

20.00

58.00

associated with inhibition of aggregation of inflammatory
cells in the airway, suppression of local production of
cytokines, prevention of mediator release, and repair of
nasal mucosal structure. Intranasal glucocorticosteroids
are well-tolerated drugs and carry a low prevalence of
side effects compared with placebo (23–25). The synthetic
corticosteroids MF, beclomethasone dipropionate,
betamethasone, dexamethasone, and hydrocortisone have
been shown to be potent against AR (26). MF is a topical
corticosteroid used commonly in AR treatment (27). In
our study, MF was used for 1 month by AR patients.
Intranasal glucocorticosteroids ameliorate AR
symptoms, but use of certain ICs can lead to local
histopathologic changes (28,29).

342

Side effects in the nasal cavity are often seen with
intranasal glucocorticosteroids. These include epithelial
irritation, burning sensations, dryness, crusting,
epistaxis, and septal perforation (8,10–12,30,31). In our
study, no patients suffered from headaches, nasal dryness,
or nasal irritation, but epistaxis was seen in one patient,
which merited exclusion from the study. It is thought
that epistaxis after IC use is due to dryness and thinning
of nasal mucosae (32,33). However, in a clinical study
by Waddell et al. (34), ICs and placebo were compared
and the prevalence of epistaxis was similar. Therefore,
epistaxis after IC use is thought to be due to exposure
of the nasal septum or anterior nasal concha to nasal
applicators.

AKKAŞ et al. / Turk J Med Sci
Table 3. Comet scores of patients.

Male
SP

Before

MF

Total

SP

After

MF

Total

Mean

Std

47.25

19.41

Number
10

Female

41.81

19.68

14

Total

44.08

19.33

24

Male

40.21

21.38

8

Female

47.29

29.29

9

Total

43.96

25.34

17

Male

44.12

20.01

18

Female

43.96

23.42

23

Total

44.03

21.72

41

Male

50.88

11.42

10

Female

49.89

18.36

14

Total

50.31

15.55

24

Male

54.58

24.30

8

Female

42.29

23.55

9

Total

48.07

23.99

17

Male

52.53

17.77

18

Female

46.92

20.38

23

Total

49.38

19.25

41

Another problem considered to be associated with
IC use is mucosal atrophy. Davies et al. (35) showed no
atrophy in the nasal mucosa due to long-term use of MF
nasal spray, and no reduction in epithelial thickness was
observed in biopsies of nasal mucosae. In another study,
atrophy in nasal mucosae was not detected after treatment
with MF nasal spray for 12 months in AR patients (31).
Minshall et al. (36) administered MF for 12 months to 69
patients with perennial rhinitis, and did not detect changes
in epithelial thickness, distribution and density of goblet
cells, morphologic characteristics of glands and vessels in
the lamina propria, or integrity of basal membranes. They
found that use of nasal spray improved the appearance of
the epithelium and reduced the prevalence of inflammatory
cell infiltrates (especially those containing eosinophils and
mast cells).
Several scholars have investigated whether ICs cause
histopathologic changes. Pipkorn et al. (37) showed
that short-term application of sprays containing MF or
budesonide to rat nasal mucosae did not cause significant
histopathologic changes. Güngör et al. (38) did not
observe significant differences in edema, ciliary loss,
or intraepithelial loss by use of budesonide in rat nasal
mucosae. Benninger et al. (39) reported that ICs did not
cause mucosal atrophy or nasal septal perforation. Cervin
et al. (8) reported that IC sprays used for AR treatment

P

0.272

cause atrophy of nasal mucosae and increase the risk of
septal perforation.
In our study, we wished to ascertain whether MF nasal
spray causes mucosal atrophy or not by observing DNA
damage in nasal mucosa cells. We did not find a significant
difference between the SP and IC groups in terms of DNA
damage, which suggests that MF does not cause mucosal
atrophy.
IC (e.g., MF, fluticasone propionate, fluticasone
furoate) use elicits minimal systemic exposure (<1%)
due to their pharmacokinetic properties, and so systemic
side effects are very limited (40). MF is an effective local
antiinflammatory topical glucocorticosteroid and is not
active systemically. Systemic effects have not been shown
in children, adolescents, or adults. MF suspensions
show little absorption in the gastrointestinal system, and
absorbed MF is excreted from urinary and biliary systems
by first-pass metabolism (31) Smith et al. (41) showed that
MF has high affinity for glucocorticoid receptors and that
its systemic absorption is minimal; thus it has minimal
side effects. In our study, MF nasal spray was used for
AR treatment because it would not lead to systemic side
effects.
Studies have shown that MF does not lead to DNA
damage in rat liver cells and that it is not genotoxic (31).
We found that MF did not cause DNA damage to nasal
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mucosa cells in either group after 4 weeks of treatment.
Hence, MF nasal spray seems to be safe for AR treatment.
In our study, SCGE was used for the determination of
DNA breaks because it is rapid, inexpensive, and only a
small number of cells was available for analyses. SCGE is
a simple, rapid, and sensitive method that can be applied
to different types of cells and DNA damage. It does not
require radioactive labeling, so it is often the preferred
method of measurement of DNA damage (18). Another
advantage is that SCGE allows the determination of DNA
breaks with small amounts of cells from human biopsies.
Moreover, the cost of equipment is lower than that of other
test methods of genotoxicity (21). In comparison to other
methods of genotoxicity testing, it can detect DNA damage
at lower levels and with higher sensitivity. Use of SCGE
in genotoxicity studies has increased gradually thanks to
such advantages (42).
Nevertheless, SCGE has disadvantages. Certain
differences (agarose concentration, number of applied

cells, electrophoresis time) at technical implementation
can affect results, and there can be differences among
results from different laboratories even if the same
protocol is applied (43). These differences occur primarily
because of the subjective nature of comet classification.
Therefore, comet counting must be undertaken by the
same experienced researcher throughout the study (18), as
was achieved in the present study.
In conclusion, we have shown, for the first time, that
treatment with MF spray for 4 weeks does not cause DNA
breaks within cells in the nasal mucosa. These data need
to be confirmed by clinical trials involving treatment with
different ICs over longer periods.
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